Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Crosby

Showing results (1-10 of 18) with videos related to

Pageof 2
Sort By:
Clinical Evidence|September 16, 2004
Malignant melanoma (non-metastatic)David Crosby, Thomas Crosby, Malcolm Mason
Clinical Evidence|April 20, 2006
Malignant melanoma (non-metastatic)Thomas Crosby, Malcolm Mason, Philip Savage
Clinical Evidence|November 24, 2004
Malignant melanoma (non-metastatic)Thomas Crosby, Malcolm Mason, Philip Savage
Clinical Evidence|May 4, 2005
Malignant melanoma (non-metastatic)Thomas Crosby, Malcolm Mason, Philip Savage
Clinical Evidence|September 17, 2002
Malignant melanoma: non-metastaticDavid Crosby, Thomas Crosby, Malcolm Mason
Bone & Joint Open|November 26, 2020
Developing a core outcome set for paediatric wrist fractures: a systematic review of prior outcomesBenjamin Thomas Crosby, Abolfazl Behbahani, Olivia Olujohungbe, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|September 13, 2017
The prognostic value of derived neutrophil to lymphocyte ratio in oesophageal cancer treated with definitive chemoradiotherapySamantha Cox, Christopher Hurt, Tal Grenader, et al.
International Journal of Radiation Oncology, Biology, Physics|December 28, 2017
Potential of Proton Therapy to Reduce Acute Hematologic Toxicity in Concurrent Chemoradiation Therapy for Esophageal CancerSamantha Warren, Christopher N Hurt, Thomas Crosby, et al.
International Journal of Radiation Oncology, Biology, Physics|October 12, 2014
Radiobiological determination of dose escalation and normal tissue toxicity in definitive chemoradiation therapy for esophageal cancerSamantha Warren, Mike Partridge, Rhys Carrington, et al.
Radiation Oncology (London, England)|February 8, 2016
The influence of dose distribution on treatment outcome in the SCOPE 1 oesophageal cancer trialRhys Carrington, Emiliano Spezi, Sarah Gwynne, et al.
Pageof 2

Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Clinical Evidence|September 16, 2004
Malignant melanoma (non-metastatic)David Crosby, Thomas Crosby, Malcolm Mason
Clinical Evidence|April 20, 2006
Malignant melanoma (non-metastatic)Thomas Crosby, Malcolm Mason, Philip Savage
Clinical Evidence|November 24, 2004
Malignant melanoma (non-metastatic)Thomas Crosby, Malcolm Mason, Philip Savage
Clinical Evidence|May 4, 2005
Malignant melanoma (non-metastatic)Thomas Crosby, Malcolm Mason, Philip Savage
Clinical Evidence|September 17, 2002
Malignant melanoma: non-metastaticDavid Crosby, Thomas Crosby, Malcolm Mason
Bone & Joint Open|November 26, 2020
Developing a core outcome set for paediatric wrist fractures: a systematic review of prior outcomesBenjamin Thomas Crosby, Abolfazl Behbahani, Olivia Olujohungbe, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|September 13, 2017
The prognostic value of derived neutrophil to lymphocyte ratio in oesophageal cancer treated with definitive chemoradiotherapySamantha Cox, Christopher Hurt, Tal Grenader, et al.
International Journal of Radiation Oncology, Biology, Physics|December 28, 2017
Potential of Proton Therapy to Reduce Acute Hematologic Toxicity in Concurrent Chemoradiation Therapy for Esophageal CancerSamantha Warren, Christopher N Hurt, Thomas Crosby, et al.
International Journal of Radiation Oncology, Biology, Physics|October 12, 2014
Radiobiological determination of dose escalation and normal tissue toxicity in definitive chemoradiation therapy for esophageal cancerSamantha Warren, Mike Partridge, Rhys Carrington, et al.
Radiation Oncology (London, England)|February 8, 2016
The influence of dose distribution on treatment outcome in the SCOPE 1 oesophageal cancer trialRhys Carrington, Emiliano Spezi, Sarah Gwynne, et al.
Pageof 2